BCM Advisors’s ResMed RMD Stock Holding History

BCM Advisors’s Portfolio RMD Stock Details RMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-215	Closed	-$13K	–	78
2016 Q4	$13K	Buy	+215	New	+$13.2K	0.01%	75

Other funds holding RMD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

CBOA

Commonwealth Bank of Australia Sydney, NSW, Australia $231M AUM

Norges Bank Oslo, Norway $935B AUM

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BCM Advisors's RMD Position: Q1 2017 in Review

BCM Advisors sold out of ResMed (RMD) in Q1 2017, closing a stake of 215 shares — an estimated $13K sold.

BCM Advisors first reported a position in RMD in Q4 2016 and held it in 1 quarter. The position peaked at $13K in Q4 2016. 374 funds tracked by Wall St. Rank hold RMD as of Q1 2017.

BCM Advisors reported no remaining ResMed position as of Q1 2017 after selling out during the quarter.
BCM Advisors sold 215 ResMed shares in Q1 2017, an estimated $13K.
BCM Advisors first reported a position in ResMed in Q4 2016 and held it in 1 quarter.
BCM Advisors's ResMed position peaked at $13K in Q4 2016.
374 funds tracked by Wall St. Rank held ResMed as of Q1 2017.

Based on BCM Advisors's 13F filing for Q1 2017, filed 12 May 2017.